奈西立肽(Nesiritide) 是一种人工合成的BNP ,VMAC等一系列研究表明,静脉应用奈西立肽治疗RHF患者,可显着改善心力衰竭症状及血流动力学状态,且无明显副...
基于240个网页-相关网页
发明技术方案涉及奈西利肽(Nesiritide)的制备方法。所述的制备方法以HMPB-AM树脂为起始原料,在缩合剂、接肽试剂的作用下,通过固相合成法依次连接具有Fmoc保护基团的氨...
基于54个网页-相关网页
Nesiritide Acetate 醋酸奈西立肽 ; 奈西立肽 ; 醋酸人脑利钠肽
Nesiritide AcetateCAS 醋酸奈西立肽
nesiritide natrecor 内西利他
Nesiritide Injection 奈西立肽注射液
Nesiritide is mainly indicated for the treatment of acute heart failure.
奈西立肽主要用于急性心力衰竭的治疗。
参考来源 - 奈西立肽——心力衰竭治疗的又一新药·2,447,543篇论文数据,部分数据来源于NoteExpress
Nesiritide is a synthetic form of brain natriuretic peptide using recombinant DNA technology.
奈西立肽是利用重组DNA技术得到的合成型人类脑利钠肽。
But metaanalyses raised the question of safety with nesiritide therapy, specifically an increased risk of renal dysfunction and mortality.
但是汇总分析发现奈西立肽有引起肾脏损害和死亡率增加的风险。
Blood pressure was lower in the nesiritide group during the first 8-12 hours of the infusion, but not later, and heart rates did not differ significantly between the treatment groups.
在给药的前8 - 12小时,奈西立肽组血压更低,其后无差异,但两组间心率无明显差异。
应用推荐